Zoltan Mari is a Neurology physician. OpenAlex indexes 216 publications with 11,727 citations (h-index 43); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
888 W Bonneville Ave
Las Vegas, NV 89106
Telephone
702-483-6000Registry record last updated 15 Sept 2017.
Clinical trials
- Personal KinetiGraph® Clinical Validation Study
Sponsor: Global Kinetics Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ACADIA Pharmaceuticals IncProgram year202551 payments$58,095openpaymentsdata.cms.gov ↗
- MDD US Operations, LLCProgram year202529 payments$32,403openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202554 payments$32,403openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
97.3%Neuromuscular Blocker97.2%Onabotulinumtoxina100%Part B, office-administered≥48 patientsgamma-Aminobutyric Acid-ergic Agonist0%Baclofen100%Part D<11 patientsNervous system
2.5%Aromatic Amino Acid Decarboxylation Inhibitor1.3%Carbidopa-Levodopa49%Rytary38%Carbidopa-Levodopa Er13%Part D≥94 patientsAtypical Antipsychotic0.3%Nuplazid57%Quetiapine Fumarate43%Part D<11 patients+ 11 more classes in this area
Cardiovascular
0.2%Beta blocker0.2%Propranolol Hcl61%Propranolol Hcl Er39%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study
npj Parkinson s Disease
2023 - The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes
Frontiers in Aging Neuroscience
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”